secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zoetis Inc. (ZTS)
CIK:        0001555280
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001555280-26-000021
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zoetis Q1 revenue flat organic; cuts FY 2026 guidance on softer demand and competition
--------------------------------------------------------------------------------

- Revenue $2.3B, +3% reported but flat organic; net income $601M ($1.42 EPS), flat YoY.
- Adjusted net income $646M ($1.53 EPS), +2% reported, +1% organic; guidance cut: FY rev $9.68-9.96B (2-5% organic growth).
- U.S. segment revenue down 8% on competitive pressure and macro price sensitivity; International up 10% organic.
- Acquisition of Neogen animal genomics business announced March 2, expected to close H2 2026.
- Pipeline includes >12 potential blockbusters; recent approvals in Canada, Thailand, Japan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1555280/000155528026000021/0001555280-26-000021-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1555280/000155528026000021/zts-20260507.htm
  HTML page:      https://secwatch.observer/filing/0001555280-26-000021

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer